Investors & Media

Press releases

Regeneron Reports First Quarter 2026 Financial and Operating Results

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.

Visit our newsroom

Upcoming & recent events

BofA Securities Health Care Conference 2026

View event details

Goldman Sachs 47th Annual Global Healthcare Conference

View event details

2026 Annual Meeting of Shareholders

Listen to webcast

View event details

View investor events

Quarterly materials

Show all

Q1 2026

Market Cap:

Apr 30, 2026 10:56 AM EDT

Minimum 15 minutes delayed. Source: LSEG

Interactive analyst center

Interactive and downloadable financial data for investors and analysts.

View analyst center

Corporate responsibility

We're dedicated to responsible business practices, integrating the highest standards of integrity into every facet of our operations.

Learn about our approach to corporate responsibility

Contact us

Investors

914.847.7741

invest@regeneron.com

Media

media@regeneron.com

Sign up for email alerts

Regeneron corporate and R&D headquarters